Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
All News
Article
Polymyalgia rheumatica (PMR) is a common disorder of the elderly that responds well to glucocorticoids (GC), but is plagued by an inability to wean off of GCs.
Article
RheumNow recentlty surveyed rheumatologists about Sjogren’s disease (SjD) - how they approach diagnosis, treatment, and unique challenges; all important as new advances in SjD evolves.
Article
A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).
Article
Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance.
Article
Epidemiologic estimates on systemic lupus erythematosus (SLE) diagnosis are limited.
Article
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology and pathology has published evidence-based guidelines for adult-onset IgA vasculitis (IgAV), which behaves very differently in adults compared to usually self-limited childhood form.
Article
A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from the U.S. market.
Article
This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.
Dr. John Cush
Tweet
True or False: A meta-analysis of 61 studies found that exercise showed anti-inflammatory trends, including reductions in CRP, IL-6, and TNF-α, in most chronic diseases.
Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/7MxkveOuZE
Dr. John Cush
Tweet
JAMA Review: Postural Orthostatic Tachycardia Syndrome (POTS)
POTS is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance.
https://t.co/dAKlTp4VK3 https://t.co/A2UvgYOQN1
Dr. John Cush
Tweet
The Scleroderma Research Foundation (SRF) will konor John Stamos with the Bob Saget Legacy Award at this year's "Cool Comedy • Hot Cuisine" ceremony that will take place Tuesday, October 13, 2026, at the Beverly Wilshire in Los Angeles. Proceeds will support the SRF https://t.co/VHIpBJrXd4
Dr. John Cush
Tweet
Japanese study of 101 864 children shows fertility treatments (ovulation induction, intrauterine insemination, invitro fertilization) increases the risk of Kawasaki Dz. Incidence rates per 100K PYs - 274 for spont conception vs 391 for assisted conception (adj HR 1.42; https://t.co/Ro0beSXAAq
Dr. John Cush
Tweet
Guidelines for Adult-Onset IgA Vasculitis
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology, and pathology published evidence-based guidelines for adult-onset IgAV, which behaves very differently in adults than the usually https://t.co/mNuL4TG9Ua
Dr. John Cush
Tweet
Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/lKBhEnTcKB
AiArthritis
Tweet
🔥 Still’s Disease Awareness Day 2026
🐉 I Won’t Be Still: Making Still’s Disease Visible
Show us a moment from your life with Still’s Disease. 📸 Share a photo/video + what “I Won’t Be Still” means to you.
For 47 hours, let’s make Still’s visible.
#MyStills #StillsDay https://t.co/B7VNmlIOQj
Dr. John Cush
Tweet
Rheum Scholarship (8.21.2026)
Dr. Cush reviews the news and journal articles from this past week on RheumNow; talking about lumbar belts, scholarships and misdiagnosis.
https://t.co/T6uggKb8n7 https://t.co/HJCMQqghaE
Dr. John Cush
Tweet
A Tribute to Thomas A. Medsger Jr., MD (1936–2026)
The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89.
https://t.co/GGC3pZVfJp https://t.co/n0ckoeQ3ZX
Dr. John Cush
Tweet
Misdiagnosis of Still's Disease
High fever, strange rashes, scary labs often lead to a consideration of Still's disease (AOSD or systemic JIA). Yet the dramatic onset of a systemic disorder may overlap with another, and possibly rarer, systemic disorder that should not be https://t.co/pSfSahO5Nw
Dr. John Cush
Tweet
JAK inhibitor Drug Market size (worldwide) was valued at $ 5.51 Billion in 2024 & is estimated to reach $ 19.81 Billion by 2033, exhibiting a Compound Annual Growth Rate of 13.66% from 2026-2033. https://t.co/1Krd1TeKv1 https://t.co/k0hx7iXTvn
